C
Christopher J. Cheng
Researcher at Yale University
Publications - 37
Citations - 3534
Christopher J. Cheng is an academic researcher from Yale University. The author has contributed to research in topics: Cancer & Gene delivery. The author has an hindex of 23, co-authored 37 publications receiving 2789 citations. Previous affiliations of Christopher J. Cheng include Alexion Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Christopher J. Cheng,Raman Bahal,Imran A. Babar,Zachary Pincus,Francisco N. Barrera,Connie Liu,Alexander A. Svoronos,Demetrios T. Braddock,Peter M. Glazer,Donald M. Engelman,W. Mark Saltzman,Frank J. Slack +11 more
TL;DR: A novel antimiR delivery platform that targets the acidic tumour microenvironment, evades systemic clearance by the liver, and facilitates cell entry via a non-endocytic pathway is introduced.
Journal ArticleDOI
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Imran A. Babar,Christopher J. Cheng,Carmen J. Booth,Xianping Liang,Joanne B. Weidhaas,W. Mark Saltzman,Frank J. Slack +6 more
TL;DR: It is shown that systemic delivery of antisense peptide nucleic acids encapsulated in unique polymer nanoparticles inhibits miR-155 and slows the growth of these “addicted” pre-B-cell tumors in vivo, suggesting a promising therapeutic option for lymphoma/leukemia.
Journal ArticleDOI
Biodegradable poly(amine- co -ester) terpolymers for targeted gene delivery
Jiangbing Zhou,Jie Liu,Christopher J. Cheng,Toral R. Patel,Caroline E. Weller,Joseph M. Piepmeier,Zhaozhong Jiang,W. Mark Saltzman +7 more
TL;DR: Targeted delivery of the pro-apoptotic TRAIL gene to tumour xenografts by one of the terpolymers results in significant inhibition of tumour growth, with minimal toxicity both in vitro and in vivo.
Journal ArticleDOI
A holistic approach to targeting disease with polymeric nanoparticles
TL;DR: This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously.
Journal ArticleDOI
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.
Kiran Musunuru,Alexandra C. Chadwick,Taiji Mizoguchi,Sara P. Garcia,Jamie E. DeNizio,Caroline W. Reiss,Kui Wang,Sowmya Iyer,Chaitali Dutta,Victoria Clendaniel,Michael Amaonye,Aaron Beach,Kathleen Berth,Souvik Biswas,Maurine C. Braun,Huei-Mei Chen,Thomas V. Colace,John D. Ganey,Soumyashree A. Gangopadhyay,Ryan Garrity,Lisa N. Kasiewicz,Jennifer Lavoie,James Madsen,Yuri Matsumoto,Anne Marie Mazzola,Yusuf S. Nasrullah,Joseph Nneji,Huilan Ren,Athul Sanjeev,Madeleine Shay,Mary R. Stahley,Steven H. Y. Fan,Ying K. Tam,Nicole M. Gaudelli,Giuseppe Ciaramella,Leslie E. Stolz,Padma Malyala,Christopher J. Cheng,Kallanthottathil G. Rajeev,Ellen Rohde,Andrew M. Bellinger,Sekar Kathiresan +41 more
TL;DR: In this article, a single infusion of lipid nanoparticles was shown to reduce levels of PCSK9 and low-density lipoprotein cholesterol in the liver of a cynomolgus macaque.